Hyaluronic acid injections to reduce knee inflammation and improve symptoms
Official title: Investigation of the Effect of Hyaluronic Acid Injection on Tnf-Alpha and IL-1beta at DNA-Protein Level in Knee Osteoarthritis Patients and Comparison With Clinical Parameters: A Randomised Controlled Trial
Run by Istanbul University · NCT06960564 · Data updated 2026-11-12
This trial will see if hyaluronic acid knee injections lower inflammatory markers (TNF‑alpha and IL‑1β) and improve pain, function, and quality of life in adults 45–75 with moderate (Kellgren‑Lawrence 2–3) knee osteoarthritis.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 45 Years to 75 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Istanbul University Academic / other |
| Locations | 1 site (Istanbul) |
| Status | Recruiting |
| Started | May 12, 2025 |
| Main results expected | September 2, 2026 |
| Study ends | September 2, 2026 |
| Registry record updated | September 3, 2026 |
| Trial ID | NCT06960564 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 45–75 with symptomatic knee osteoarthritis (Kellgren‑Lawrence stage 2–3), knee pain for more than three months resistant to conservative care, and able to attend visits at the study site are ideal candidates.
✕Probably not a fit
Patients with KL stage 1 or 4, secondary or inflammatory arthritis, recent major knee trauma, uncontrolled systemic illness, a bleeding tendency, BMI >40, pregnancy, or recent joint replacement are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults aged 45–75 with Kellgren‑Lawrence stage 2–3 knee osteoarthritis and at least three months of pain despite conservative treatment will be enrolled. Participants receive intra‑articular hyaluronic acid injections or a saline placebo and pre‑ and post‑treatment TNF‑alpha and IL‑1β levels will be measured in blood and synovial fluid, along with DNA methylation changes. Patient‑reported pain, functional status, and quality of life will be recorded and correlated with biomarker changes. The trial is conducted at Istanbul University Faculty of Medicine and funded by the Istanbul University Research Fund.
Why it matters
Potential benefit: If successful, the treatment could lower joint inflammation markers and lead to reduced pain and improved function and quality of life for people with moderate knee osteoarthritis.
How similar studies have gone: Previous trials of intra‑articular hyaluronic acid have shown modest symptom improvements for some patients, but effects on TNF‑alpha, IL‑1β, and epigenetic methylation in blood and synovial fluid are not well established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of knee osteoarthritis according to ACR (American College of Rheumatology) criteria * Knee pain for more than 3 months * Presence of knee pain resistant to conservative treatment for at least 3 months * To be between the ages of 45-75 * Kellgren-Lawrence stage 2-3 gonarthrosis detected in the available knee direct radiographs of the patients Exclusion Criteria: * Patients with KL stage 1 and 4 OA * Systematic diseases (severe cardiovascular disease, severe renal failure, severe hepatic failure, uncontrolled diabetes, cancer, immunosuppression, haematological diseases, systemic bone diseases) * Bleeding tendency (acquired or inherited) \[lNR\>2 in a patient on Coumadin\], * Infection (systemic or local) * Secondary knee osteoarthritis (inflammatory joint disease, post-traumatic, post-infectious, etc.) * Major knee trauma within the last 1 year * BMI \>40 * History of total knee or hip arthroplasty within 1 year * Pregnancy * History of intra-articular injection within the last 6 months * Patients with Hb less than 11 g/dl and Plt less than 150.000 * Presence of allergy to hyaluronic acid products
Where it's running
-
Istanbul University, Istanbul Faculty of Medicine
Istanbul, Turkey (Türkiye) Recruiting
Study contacts
- Study coordinator: Dicle Rotinda Özdaş Sevgin
- Email: rotindaozdas95@gmail.com
- Phone: +90 530-141-5940
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Botulinum toxin vs hyaluronic acid injections for knee osteoarthritis
This study tests whether injecting botulinum toxin or hyaluronic acid directly into the knee provides better pain relief for people with knee osteoarthritis.
-
Combined PRP and hyaluronic acid injections for knee osteoarthritis
This study sees if giving a mix of platelet-rich plasma and hyaluronic acid into the knee helps people with osteoarthritis.
-
Effects of virtual reality on walking in adults with knee osteoarthritis
This study tests how immersive virtual reality environments—designed to feel safe or to provoke fear—affect walking and worry about movement in adults 50 and older with knee osteoarthritis and in healthy peers.
-
Improved Facial Skin Quality After VYC-12L for Breast Cancer Survivors
This study tests whether intradermal injections of VYC-12L can improve facial skin quality and quality of life in adults who have completed breast cancer treatment.
-
Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese
This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).
-
Autologous adipose-derived stem cell injections for knee osteoarthritis
We’re testing whether injecting a patient’s own fat-derived stem cells into the knee can help people with knee OA feel less pain and move better, compared with a standard hyaluronic acid treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.